Literature DB >> 12010878

Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study.

.   

Abstract

BACKGROUND AND AIMS: The development of atrophic chronic gastritis (ACG) is multifactorial, involving environment as well as host responses to Helicobacter pylori infection. The aim of this study was to determine factors involved in ACG in a European dyspeptic population.
METHODS: Data concerning sociodemographics, social behaviour, biological aspects, diet, and virulence factors of H pylori strains were collected in a cross sectional study from 19 European centres in 14 countries. Dyspeptic H pylori positive patients with ACG or non-ACG (NACG) at histology were included. Anti-CagA antibodies were evaluated by two immunoblot tests and anti-VacA antibodies by one. Logistic regression models were constructed, and estimated odds ratios (ORs) and 95% confidence intervals (95% CI) were calculated from the coefficients.
RESULTS: Of the 451 patients included in the study, 267 were analysed: 202 had NACG and 65 ACG. Mean age was 44.4 years and 63% were women. Risk factors for atrophy identified by multivariate analysis were: age over 60 years (OR 4.14, 95% CI 1.79-9.58), coffee consumption (OR 2.35, 95% CI 1.07-5.16), sedative consumption (OR 2.17, 95% CI 1.04-4.52), and harbouring anti-CagA and anti-VacA antibodies simultaneously (OR 3.09, 95% CI 1.26-7.56), while the odds were significantly reduced for those with an anxiety score of 6 or more (OR 0.45, 95% CI 0.21-0.99).
CONCLUSION: The simultaneous presence of anti-CagA and anti-VacA antibodies enhanced the risk of ACG in European dyspeptic patients. Failure to discern diet and family history as risk factors for ACG may suggest that diet is homogeneous in Europe and that most of the risk factors for ACG identified so far are identical to risk factors for H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010878      PMCID: PMC1773225          DOI: 10.1136/gut.50.6.779

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  62 in total

1.  Carcinoma and intestinal metaplasia of the stomach in Colombian migrants.

Authors:  P Correa; C Cuello; E Duque
Journal:  J Natl Cancer Inst       Date:  1970-02       Impact factor: 13.506

2.  Individual and joint contribution of family history and Helicobacter pylori infection to the risk of gastric carcinoma.

Authors:  H Brenner; V Arndt; T Stürmer; C Stegmaier; H Ziegler; G Dhom
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

3.  HLA-DQB1 locus and the development of atrophic gastritis with Helicobacter pylori infection.

Authors:  T Sakai; N Aoyama; K Satonaka; S Shigeta; H Yoshida; Y Shinoda; D Shirasaka; M Miyamoto; Y Nose; M Kasuga
Journal:  J Gastroenterol       Date:  1999       Impact factor: 7.527

4.  Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori.

Authors:  E M El-Omar; K Oien; L S Murray; A El-Nujumi; A Wirz; D Gillen; C Williams; G Fullarton; K E McColl
Journal:  Gastroenterology       Date:  2000-01       Impact factor: 22.682

5.  Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival.

Authors:  D Capuzzi; E Santoro; W W Hauck; A J Kovatich; F E Rosato; R Baffa; K Huebner; P A McCue
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

6.  Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study.

Authors:  F Mégraud; N Lehn; T Lind; E Bayerdörffer; C O'Morain; R Spiller; P Unge; S V van Zanten; M Wrangstadh; C F Burman
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

7.  Studies of patients with atrophic gastritis: a 10-15-year follow-up.

Authors:  M Siurala; K Varis; M Wiljasalo
Journal:  Scand J Gastroenterol       Date:  1966       Impact factor: 2.423

8.  The beneficial effect of corticosteroids in a patient with simple atrophic gastritis. A case report.

Authors:  B Fixa; O Komárková; V Herout
Journal:  Scand J Gastroenterol       Date:  1967       Impact factor: 2.423

9.  Helicobacter pylori gastritis in Africa.

Authors:  E J Kuipers; G A Meijer
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-06       Impact factor: 2.566

Review 10.  Intestinal metaplasia, atrophic gastritis and stomach cancer: trends over time.

Authors:  P Sipponen; K Kimura
Journal:  Eur J Gastroenterol Hepatol       Date:  1994-12       Impact factor: 2.566

View more
  13 in total

1.  Family history is an independent risk factor for the progression of gastric atrophy among patients with Helicobacter pylori infection.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kosuke Sakitani; Hiroharu Yamashita; Shuntaro Yoshida; Keisuke Hata; Takamitsu Kanazawa; Naoto Fujiwara; Takanori Kanai; Naohisa Yahagi; Osamu Toyoshima
Journal:  United European Gastroenterol J       Date:  2016-06-22       Impact factor: 4.623

Review 2.  The Emerging Health Benefits of Coffee with an Emphasis on Type 2 Diabetes and Cardiovascular Disease.

Authors:  Siamak Bidel; Jaakko Tuomilehto
Journal:  Eur Endocrinol       Date:  2013-08-23

3.  Prevalence of Helicobacter pylori infection in male patients with osteoporosis and controls.

Authors:  N Figura; L Gennari; D Merlotti; C Lenzi; S Campagna; B Franci; B Lucani; L Trabalzini; L Bianciardi; C Gonnelli; A Santucci; A Nut
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

Review 4.  Diagnosis of Helicobacter pylori: what should be the gold standard?

Authors:  Saurabh Kumar Patel; Chandra Bhan Pratap; Ashok Kumar Jain; Anil Kumar Gulati; Gopal Nath
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Immunological and morphogenic basis of gastric mucosa atrophy and metaplasia.

Authors:  Gerhard Faller; Thomas Kirchner
Journal:  Virchows Arch       Date:  2004-12-04       Impact factor: 4.064

6.  Evaluation of a commercial immunoblot, Helicoblot 2.1, for diagnosis of Helicobacter pylori infection.

Authors:  Lea Veijola; Aino Oksanen; Pentti Sipponen; Hilpi Rautelin
Journal:  Clin Vaccine Immunol       Date:  2008-09-30

7.  Role of vacuolating cytotoxin VacA and cytotoxin-associated antigen CagA of Helicobacter pylori in the progression of gastric cancer.

Authors:  Mi-Ran Ki; Meeyul Hwang; Ah-Young Kim; Eun-Mi Lee; Eun-Joo Lee; Myeong-Mi Lee; Soo-Eun Sung; Sang-Hyeob Kim; Hye Seung Lee; Kyu-Shik Jeong
Journal:  Mol Cell Biochem       Date:  2014-07-20       Impact factor: 3.396

8.  UreA and cagA genes of Helicobacter pylori in Egyptian patients with laryngeal squamous cell carcinoma and benign laryngeal polyps: a cohort study.

Authors:  Ghada Barakat; Yasmin Nabiel; Omima Ali; Ghada El-Nady; Ahmed Musaad; Asser El-Sharkawy
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-05-25       Impact factor: 2.503

Review 9.  Helicobacter pylori detection and antimicrobial susceptibility testing.

Authors:  Francis Mégraud; Philippe Lehours
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

10.  Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics.

Authors:  N Broutet; M Plebani; C Sakarovitch; P Sipponen; F Mégraud
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.